The Disciplinary Committee of Nasdaq Stockholm has resolved that AegirBio shall pay fees

The Disciplinary Committee of Nasdaq Stockholm has resolved that AegirBio shall pay fees as a consequence of the company’s disclosures of information to the market. The fees amount to eight (8)] annual fees, corresponding to approximately 1, 255 MSEK.

The resolution means that the agreement with Atlas Special Opportunities, LLC regarding convertibles amounting to MSEK 55 with attached warrants, which was made public on 20 December 2022, will be fulfilled in accordance with its terms and conditions.

“AegirBio has been informed that the Disciplinary Committee of Nasdaq Stockholm has resolved to not delist AegirBio and instead order the company to pay fees. In our opinion, it is the correct resolution to not comply with Nasdaq Stockholm’s request for delisting. The company is hereby putting a highly turbulent time behind it and is looking forward to focusing on its core business”, says Bradley Messmer, CEO of AegirBio.